A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Ocellaris Pharma, Inc.
University of Virginia
Sotio Biotech Inc.
Cellestia Biotech AG
Fate Therapeutics
Eli Lilly and Company
Effector Therapeutics
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins